• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Vaginal Atrophy - Pipeline Review, H1 2012 Product Image

Vaginal Atrophy - Pipeline Review, H1 2012

  • ID: 2092619
  • March 2012
  • 55 pages
  • Global Markets Direct

Vaginal Atrophy – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Vaginal Atrophy - Pipeline Review, H1 2012', provides an overview of the Vaginal Atrophy therapeutic pipeline. This report provides information on the therapeutic development for Vaginal Atrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vaginal Atrophy. 'Vaginal Atrophy - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Vaginal Atrophy.
- A review of the Vaginal Atrophy products under development by companies and universities/research institutes based on READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Vaginal Atrophy Overview
Therapeutics Development
An Overview of Pipeline Products for Vaginal Atrophy
Vaginal Atrophy Therapeutics under Development by Companies
Vaginal Atrophy Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Vaginal Atrophy Therapeutics – Products under Development by Companies
Vaginal Atrophy Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Vaginal Atrophy Therapeutics Development
Shionogi & Co., Ltd.
Arkopharma SA
Bayer AG
Bionovo, Inc.
Pear Tree Pharmaceuticals
Pantarhei Bioscience BV
Vaginal Atrophy – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Estetrol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Seala - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ophena - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Phyto Soya Vaginal Gel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
clino-san - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PT-200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PT-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Estradiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Estriol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaginorm - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaginal Atrophy Therapeutics – Discontinued Products
Vaginal Atrophy Therapeutics - Dormant Products
Vaginal Atrophy – Product Development Milestones
Featured News & Press Releases
May 12, 2010: Ospemifene May Be Safe, Effective for Vulvovaginal Atrophy
Mar 02, 2010: Shionogi Enters Into Exclusive License Agreement With Quatrx Pharmaceuticals To Market Ospemifene
Sep 10, 2009: Quatrx Announces Positive Results Of Second Pivotal Phase 3 Clinical Study For Ophena (Ospemifene Tablets) In Treatment Of Postmenopausal Vaginal Atrophy
Jul 29, 2009: Quatrx Announces Further Positive Phase 3 Results for ophena (ospemifene tablets) in postmenopausal vaginal atrophy
Mar 31, 2009: Quatrx Completes Erollment Of Ophena (ospemifene tablets) Final Pivotal Phase 3 Study In Women With Postmenopausal Vaginal Atrophy
Sep 26, 2008: Bionovo's VG101 Shows Greater Efficacy Than Estrogen In The Treatment Of Vaginal Dryness
Sep 24, 2008: Quatrx Pharmaceuticals Announces Additional Data From Phase 3 Study For Ophena (Ospemifene Tablets) Showing Improvements In Clinical Symptoms Of Vulvovaginal Atrophy
Sep 04, 2008: Quatrx Initiates Second Phase 3 Study Of Ophena (ospemifene tablets) In Women With Postmenopausal Vaginal Syndrome
Jun 16, 2008: Quatrx Pharmaceuticals Presents Results From Ophena (Ospemifene Tablets) Phase 3 Study Related To Treatment Of Symptoms Of Vulvovaginal Atrophy
May 21, 2008: Quatrx Pharmaceuticals Announces Presentation Of Further Data From Ophena (Ospemifene) Phase 3 Study For Treatment Of Symptoms Of VulvoVaginal Atrophy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Vaginal Atrophy, H1 2012
Products under Development for Vaginal Atrophy – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Shionogi & Co., Ltd., H1 2012
Arkopharma SA, H1 2012
Bayer AG, H1 2012
Bionovo, Inc., H1 2012
Pear Tree Pharmaceuticals, H1 2012
Pantarhei Bioscience BV, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Vaginal Atrophy Therapeutics – Discontinued Products
Vaginal Atrophy Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Vaginal Atrophy, H1 2012
Products under Development for Vaginal Atrophy – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos